The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials
- 316 Downloads
In our systematic review and meta-analysis, we comprehensively evaluated menatetrenone in the management of osteoporosis. We found that menatetrenone decreased the ratio of undercarboxylated osteocalcin to osteocalcin (ucOC/OC) and improved lumbar BMD compared with placebo based on the 18 studies assessed. However, its benefit in fracture risk control was uncertain.
We performed a systematic review and meta-analysis of the efficacy and safety of menatetrenone in managing osteoporosis.
PubMed, Cochrane Library, Embase, ClinicalTrials.gov, and three Chinese literature databases (CNKI, CBM, Wanfang) were searched for relevant randomized controlled trials (RCTs) published before October 5, 2017, comparing menatetrenone with other anti-osteoporotic drugs or placebo in treating osteoporosis. The pooled risk ratio (RR) or mean difference (MD) and 95% confidence interval (CI) were calculated using fixed-effects or random-effects meta-analysis.
Eighteen RCTs (8882 patients) were included. Pooled analyses showed that menatetrenone was more effective than placebo in improving lumbar bone mineral density (BMD) (five studies, N = 658, MD = 0.05 g/cm2, 95% CI 0.01 to 0.09 g/cm2) and decreasing ucOC/OC (two studies, N = 75, MD = − 21.78%, 95% CI − 33.68 to − 9.87%). Compared with placebo, menatetrenone was associated with a nonsignificantly decreased risk of vertebral fracture (five studies, N = 5508, RR = 0.87, 95% CI 0.64 to 1.20). Evidence on other anti-osteoporotic drugs as comparators was limited and revealed no significantly different effects of menatetrenone on BMD or fracture risks. Furthermore, compared with placebo, menatetrenone significantly increased the incidence of adverse events (AEs) (two studies, N = 1949, RR = 1.47, 95% CI 1.07 to 2.02) and adverse drug reactions (four studies, N = 6102, RR = 1.29, 95% CI 1.07 to 1.56). However, no significant difference in the incidence of serious AEs was found between menatetrenone and placebo.
Menatetrenone significantly decreases ucOC and might improve lumbar BMD in osteoporotic patients. However, its benefit in fracture risk control is uncertain.
KeywordsMenatetrenone Osteoporosis Efficacy Safety Meta-analysis
Compliance with ethical standards
Conflicts of interest
- 1.International Osteoporosis Foundation. https://www.iofbonehealth.org/what-osteoporosis-0. Accessed 1 May 2018
- 3.Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307:1248–1250. https://doi.org/10.1136/bmj.307.6914.1248
- 6.Briggs AM, Cross MJ, Hoy DG, Sànchez-Riera L, Blyth FM, Woolf AD, March L (2016) Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization world report on aging and health. Gerontologist 56(Suppl 2):S243–S255. https://doi.org/10.1093/geront/gnw002 CrossRefPubMedGoogle Scholar
- 7.Delmas PD (2002) Treatment of postmenopausal osteoporosis. N Engl J Med 359:736–746Google Scholar
- 9.Urayama S, Kawakami A, Nakashima T, Tsuboi M, Yamasaki S, Hida A, Ichinose Y, Nakamura H, Ejima E, Aoyagi T (2000) Effect of vitamin K 2 on osteoblast apoptosis: vitamin K 2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J Lab Clin Med 136:181–193CrossRefPubMedGoogle Scholar
- 12.Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW (2015) Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int 26:1175–1186. https://doi.org/10.1007/s00198-014-2989-6 CrossRefPubMedGoogle Scholar
- 17.Higgins J, Green SE (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. http://handbook-5-1.cochrane.org/ Accessed 22 November 2017
- 18.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Epidemiol Biostat Public Health 6:e1–e34Google Scholar
- 20.Steichen T (2001) METANINF: Stata module to evaluate influence of a single study in meta-analysis estimation. Stat Softw Components. http://ideas.repec.org/c/boc/bocode/s419201.html Accessed 4 Sept 2018
- 23.Orimo H, Fujita T, Onomura T, Inoue T, Kushida K, Shiraki M (1992) Clinical evaluation of Ea-0167 (menatetrenone) in the treatment of osteoporosis. Phase III double-blind multicenter comparative study with alfacalcidol. Clin Eval 20:45–100Google Scholar
- 25.Iwamoto J, Takeda T, Ichimura S (2001) Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci 6:487–492. https://doi.org/10.1007/s007760100002 CrossRefPubMedGoogle Scholar
- 27.Miki T, Nakatsuka K, Naka H, Kitatani K, Saito S, Masaki H, Tomiyoshi Y, Morii H, Nishizawa Y (2003) Vitamin K(2) (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metab 21:161–165. https://doi.org/10.1007/s007740300025 CrossRefPubMedGoogle Scholar
- 28.Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med 117:549–555. https://doi.org/10.1016/j.amjmed.2004.05.019 CrossRefPubMedGoogle Scholar
- 29.Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, Sato T, Yamazaki K (2009) Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab 27:66–75. https://doi.org/10.1007/s00774-008-0008-8 CrossRefPubMedGoogle Scholar
- 30.Shiraki M, Itabashi A (2009) Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study. J Bone Miner Metab 27:333–340. https://doi.org/10.1007/s00774-008-0034-6 CrossRefPubMedGoogle Scholar
- 31.Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chida S, Shimada Y (2014) Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab 32:290–297. https://doi.org/10.1007/s00774-013-0490-5 CrossRefPubMedGoogle Scholar
- 32.Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2017) Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab 35:385–395. https://doi.org/10.1007/s00774-016-0768-5 CrossRefPubMedGoogle Scholar
- 33.Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW (2014) Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin Interv Aging 9:121–127. https://doi.org/10.2147/cia.s54107 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Liu L (2015) The efficacy of vitamin K2 in treating osteoporotic patients and its effects on patients’ coagulation function. Master thesis. Jilin University. http://cdmd.cnki.com.cn/Article/CDMD-10183-1015591169.htm. Accessed 20 October 2017
- 35.Hu H, You M, Ran J (2017) The efficacy and safety of menatetrenone soft capsules combined with Salmon calcitonin in the treatment of elderly osteoporosis. Chin J Osteoporos 23:643–646Google Scholar
- 36.Luo J, Nie G, Huang X, Yang S, Xin J (2017) The effect of menatetrenone soft capsules with Caltrate Din the treatment of osteoporosis and femoral intertrochanteric fracture and its effect on bone metabolism index. Anhui Med Pharm J 21:1101–1105Google Scholar
- 37.Zhuang H, Chen D, Xu M, Su Q, Dong T (2017) The effect of vitamin K2 on the prevention and treatment of postmenopausal osteoporosis and serum cathepsin K. Chin J Osteoporosis 23:627–630 and 651Google Scholar
- 44.Fujita Y, Iki M, Tamaki J, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N (2012) Association between vitamin K intake from fermented soybeans, natto, and bone mineral density in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int 23:705–714. https://doi.org/10.1007/s00198-011-1594-1 CrossRefPubMedGoogle Scholar